CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that presentations from studies evaluating its novel Toll-like Receptor (TLR) antagonist candidates in preclinical models of lung inflammation and psoriasis were made at the Federation of Clinical Immunology Societies (FOCIS) 2008 Annual Meeting held in Boston, MA, June 5-9.
